Detalhe da pesquisa
1.
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Nature
; 538(7623): 114-117, 2016 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27680702
2.
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Blood
; 129(16): 2233-2245, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28096095
3.
Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Int J Mol Sci
; 20(19)2019 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31569391
4.
Decrypting the PAK4 transcriptome profile in mammary tumor forming cells using Next Generation Sequencing.
Genomics
; 2017 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055713
5.
Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Gut
; 66(8): 1358-1368, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27196599
6.
Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Kidney Int
; 92(4): 922-933, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28545714
7.
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
Am J Hematol
; 97(2): E54-E58, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34817872
8.
XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells.
J Cell Physiol
; 231(12): 2711-9, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26991404
9.
Clinical translation of nuclear export inhibitors in cancer.
Semin Cancer Biol
; 27: 74-86, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24755012
10.
Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
BMC Cancer
; 15: 910, 2015 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26573568
11.
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
bioRxiv
; 2023 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37034616
12.
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Mol Cancer Ther
; 22(12): 1422-1433, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37703579
13.
PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
Cancers (Basel)
; 14(1)2021 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35008323
14.
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mol Cancer Ther
; 20(10): 1836-1845, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34253597
15.
A structurally tunable DNA-based extracellular matrix.
J Am Chem Soc
; 132(42): 14727-9, 2010 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20925350
16.
Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer.
Kidney360
; 1(5): 376-388, 2020 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35224510
17.
PAK4 inhibition improves PD-1 blockade immunotherapy.
Nat Cancer
; 1(1): 46-58, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-34368780
18.
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.
Blood Adv
; 4(3): 586-598, 2020 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32045477
19.
Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.
Small GTPases
; 10(5): 367-377, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28641032
20.
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
Cancers (Basel)
; 11(12)2019 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31795447